OR WAIT null SECS
Accord Healthcare today announced further expansion in Europe with the opening of a new operation in Basel, Switzerland and further expansion of operations in Austria. These moves follow news of the company’s recent commitment in the UK through the investment of a manufacturing site in Fawden, Newcastle-upon-Tyne.
Already among the largest supplier of medicines in the UK and the most significant provider of chemotherapy in the European Union countries, the company says it will launch “a large pipeline of generics, biosimilars and novel pharmaceuticals over the coming years, with a focus in therapeutic areas such as oncology, critical care, auto-immune and central nervous system conditions”.
Richard Hummel, Accord’s Country Manager, Switzerland, commented: “Switzerland is renowned for its pharmaceutical, biotechnology and science industry that attracts international talent. We plan to bring that talent into the Accord family to help us achieve our global vision to be a major top 5 pan-region generics company by 2021.”
Ewald Sternad, Country Manager, Austria, added: “We are delighted to continue the growth trajectory that we have already achieved in Austria... These investments are a result of doubling market share of our targeted chemotherapy product and the increase of sales emanating from secondary-care prescribers.”